RA Capital Management 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 89 US equity positions worth $7.6bn in its Q4 2024 13F filing. The largest position was ASND at 18.4% of the reported book, followed by PCVX and JANX. Against the Q3 2024 filing, it opened 6 new positions, added to 7 and reduced 10 among the top 50 holdings.
What did RA Capital Management own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 18.4% | $1.4bn | 10,112,744 | 4% | added |
| 2 | PCVX VAXCYTE INC | Healthcare | 9.4% | $711.3m | 8,689,190 | 0% | held |
| 3 | JANX JANUX THERAPEUTICS INC | Healthcare | 7.3% | $555.0m | 10,365,652 | 13% | added |
| 4 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 4.5% | $340.6m | 6,084,412 | 0% | held |
| 5 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 3.2% | $244.3m | 7,506,934 | 0% | held |
| 6 | EWTX EDGEWISE THERAPEUTICS INC | 3.1% | $237.9m | 8,909,091 | 0% | held | |
| 7 | NEWAMSTERDAM PHARMA CO NV | 3.0% | $227.3m | 8,845,000 | 10% | added | |
| 8 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 3.0% | $225.2m | 18,202,009 | 0% | held |
| 9 | ARCELLX INC | 2.8% | $213.8m | 2,787,327 | 51% | added | |
| 10 | AVIDITY BIOSCIENCES INC | 2.4% | $183.2m | 6,300,408 | 0% | held | |
| 11 | SEPN SEPTERNA INC | 2.1% | $160.2m | 6,995,858 | – | new | |
| 12 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.0% | $150.3m | 6,381,144 | 0% | held |
| 13 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.0% | $147.9m | 10,637,290 | 2% | added |
| 14 | RXST RXSIGHT INC | Healthcare | 1.7% | $128.7m | 3,743,018 | -4% | reduced |
| 15 | BCAX BICARA THERAPEUTICS INC | 1.6% | $121.2m | 6,955,993 | 0% | held | |
| 16 | LENZ LENZ THERAPEUTICS INC | Healthcare | 1.6% | $120.6m | 4,178,823 | 0% | held |
| 17 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 1.5% | $114.6m | 10,860,977 | 0% | held |
| 18 | 89BIO INC | 1.5% | $110.9m | 14,175,398 | 0% | held | |
| 19 | XBI SPDR S&P BIOTECH ETF | 1.5% | $110.6m | 1,228,240 | – | new | |
| 20 | GERN GERON CORP | Healthcare | 1.4% | $106.2m | 30,009,536 | -7% | reduced |
| 21 | CLYM CLIMB BIO INC | 1.4% | $104.2m | 31,419,267 | 0% | held | |
| 22 | ARTV ARTIVA BIOTHERAPEUTICS INC | 1.3% | $99.3m | 9,853,302 | 0% | held | |
| 23 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.1% | $84.6m | 1,000,000 | 0% | held |
| 24 | VRNA VERONA PHARMA PLC - ADR | 1.1% | $82.1m | 1,766,830 | -65% | reduced | |
| 25 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.0% | $72.9m | 5,755,577 | -27% | reduced | |
| 26 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.9% | $71.1m | 1,569,491 | -20% | reduced |
| 27 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.8% | $59.7m | 4,850,984 | 0% | held |
| 28 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.8% | $58.6m | 761,955 | 0% | held |
| 29 | RXRX RECURSION PHARMACEUTICALS-A | Healthcare | 0.7% | $52.2m | 7,725,096 | -50% | reduced |
| 30 | TOURMALINE BIO INC | 0.7% | $51.5m | 2,538,925 | 0% | held | |
| 31 | ACRV ACRIVON THERAPEUTICS INC | 0.7% | $50.2m | 8,340,508 | 0% | held | |
| 32 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.6% | $48.1m | 10,229,099 | 0% | held |
| 33 | TXG 10X GENOMICS INC-CLASS A | Healthcare | 0.6% | $47.1m | 3,279,401 | – | new |
| 34 | GHRS GH RESEARCH PLC | 0.6% | $46.8m | 6,686,689 | 0% | held | |
| 35 | ASTRIA THERAPEUTICS INC | 0.6% | $45.6m | 5,105,213 | 0% | held | |
| 36 | VOR VOR BIOPHARMA INC | 0.6% | $44.0m | 39,646,039 | 74% | added | |
| 37 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.5% | $41.2m | 1,517,418 | -20% | reduced |
| 38 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.5% | $40.7m | 1,866,400 | -20% | reduced |
| 39 | PEPG PEPGEN INC | Healthcare | 0.5% | $40.5m | 10,689,545 | 0% | held |
| 40 | EVH EVOLENT HEALTH INC - A | Healthcare | 0.5% | $40.2m | 3,577,197 | -58% | reduced |
| 41 | KURA KURA ONCOLOGY INC | Healthcare | 0.5% | $38.8m | 4,451,041 | – | new |
| 42 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.5% | $34.6m | 1,347,252 | 0% | held |
| 43 | ZLAB ZAI LAB LTD-ADR | Healthcare | 0.4% | $33.9m | 1,295,040 | – | new |
| 44 | CHIMERIX INC | 0.4% | $30.6m | 8,800,000 | 0% | held | |
| 45 | CDTX CIDARA THERAPEUTICS INC | 0.4% | $29.4m | 1,092,796 | 55% | added | |
| 46 | MBX MBX BIOSCIENCES INC | Healthcare | 0.4% | $27.9m | 1,511,334 | 0% | held |
| 47 | NKTX NKARTA INC | Healthcare | 0.4% | $26.9m | 10,805,129 | 0% | held |
| 48 | ABOS ACUMEN PHARMACEUTICALS INC | 0.3% | $25.7m | 14,932,063 | 0% | held | |
| 49 | 4D MOLECULAR THERAPEUTICS IN | 0.3% | $25.4m | 4,563,211 | -10% | reduced | |
| 50 | NRIX NURIX THERAPEUTICS INC | Healthcare | 0.3% | $25.1m | 1,333,333 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.